Capmatinib

136 interactions 289 cited references

Also sold as: Tabrecta Tabrecta®

About Capmatinib

Capmatinib is used to treat a certain type of non-small cell lung cancer (NSCLC) that has spread to other parts of the body. Capmatinib is in a class of medications called kinase inhibitors. It works by blocking the action of an abnormal protein that signals cancer cells to multiply. This helps slow or stop the spread… Read the full Capmatinib drug information page →

Medically reviewed by Dr. Brian Staiger, PharmD, BCPS · Updated Aug 9, 2026 · Editorial policy · Data sources

Sources: FDA prescribing information (Structured Product Labeling), the published literature cited in each entry, DDInter 2.0 (a major open-access drug-interaction database), and legacy DrugBank interaction data distributed by the NIH's RxNav service (decommissioned in 2024) — analyzed and reviewed by our pharmacist team. How we build this library →

Most serious with: Rubella Virus Vaccine, Live Typhoid Vaccine Bacillus Of Calmette And Guerin Vaccine, Live Varicella Virus Vaccine, Live Smallpox Monkeypox Vaccine Yellow Fever Vaccine

11 Contraindicated 120 Major 5 Moderate

All (136) Contraindicated (11) Major (120) Moderate (5)

Major

Capmatinib Fexofenadine Allegra Increased P-gp substrate exposure and an increased risk of increased adverse reactions Details Capmatinib Fosphenytoin Cerebyx Decreased capmatinib exposure and reduction of antitumor activity Details Capmatinib Gilteritinib Xospata Increased P-gp substrate exposure and an increased risk of increased adverse reactions Details Capmatinib Glecaprevir Increased P-gp substrate exposure and an increased risk of increased adverse reactions Details Capmatinib Influenza Virus Vaccine, Live An increased risk of infection by the live vaccine Details Capmatinib Irinotecan Camptosar Increased BCRP substrate exposure and an increased risk of adverse reactions Details Capmatinib Itraconazole Sporanox Increased CYP3A4 substrate exposure and an increased risk of CYP3A4 substrate-related adverse effects Details Capmatinib Lapatinib Tykerb Increased P-gp substrate exposure and an increased risk of increased adverse reactions Details Capmatinib Ledipasvir Increased P-gp substrate exposure and an increased risk of increased adverse reactions Details Capmatinib Lefamulin Xenleta Increased lefamulin exposure and an increased risk of lefamulin-related adverse reactions Details Capmatinib Letermovir Prevymis Increased CYP3A substrate exposure Details Capmatinib Loperamide Diamode An increased loperamide exposure and an increased risk of increased adverse reactions Details Capmatinib Lorlatinib Lorbrena Decreased capmatinib exposure and reduction of antitumor activity Details Capmatinib Lumacaftor Decreased capmatinib exposure and reduction of antitumor activity Details Capmatinib Maraviroc Selzentry Increased P-gp substrate exposure and an increased risk of increased adverse reactions Details Capmatinib Mavorixafor Xolremdi Increased mavorixafor exposure and an increased risk of mavorixafor-related adverse effects Details Capmatinib Metformin Fortamet® Increased exposure of MATE1 and MATE2K substrates and risk of increased adverse reactions Details Capmatinib Methotrexate Jylamvo Increased BCRP substrate exposure and an increased risk of adverse reactions Details Capmatinib Mexiletine Mexitil® Increased CYP1A2 substrate exposure and an increased risk of adverse reactions Details Capmatinib Mifepristone Korlym Increased CYP3A4 substrate exposure Details Capmatinib Mitotane Lysodren Decreased capmatinib exposure and reduction of antitumor activity Details Capmatinib Modafinil Provigil Decreased capmatinib exposure and reduction of antitumor activity Details Capmatinib Morphine Increased morphine exposure and an increased risk of morphine-related adverse effects (hypotension, respiratory depression, profou... Details Capmatinib Morphine Sulfate Liposome Increased morphine exposure and an increased risk of morphine-related adverse effects (hypotension, respiratory depression, profou... Details Capmatinib Nafcillin Decreased capmatinib exposure and reduction of antitumor activity Details Capmatinib Naldemedine Symproic Increased P-gp substrate exposure and an increased risk of increased adverse reactions Details Capmatinib Nintedanib Ofev Increased P-gp substrate exposure and an increased risk of increased adverse reactions Details Capmatinib Olanzapine Increased CYP1A2 substrate exposure and an increased risk of adverse reactions Details Capmatinib Omaveloxolone Skyclarys Reduced CYP3A4 substrate exposure and reduced efficacy of CYP3A4 substrate Details Capmatinib Ondansetron Increased CYP1A2 substrate exposure and an increased risk of adverse reactions Details Capmatinib Ozanimod Increased BCRP substrate exposure and an increased risk of adverse reactions Details Capmatinib Paclitaxel Abraxane Increased PACLitaxel exposure Details Capmatinib Paclitaxel Protein-Bound Increased PACLitaxel exposure Details Capmatinib Phenobarbital Fidoquel Decreased capmatinib exposure and reduction of antitumor activity Details Capmatinib Phenytoin Dilantin Decreased capmatinib exposure and reduction of antitumor activity Details Capmatinib Pibrentasvir Increased P-gp substrate exposure and an increased risk of increased adverse reactions Details Capmatinib Pimozide Increased pimozide exposure and an increased risk of pimozide-related adverse reactions Details Capmatinib Pirfenidone Esbriet Increased CYP1A2 substrate exposure and an increased risk of adverse reactions Details Capmatinib Posaconazole Noxafil Increased posaconazole exposure and an increased capmatinib exposure Details Capmatinib Primidone Mysoline Decreased capmatinib exposure and reduction of antitumor activity Details

Check another drug

Still have questions about this combination?

Every question gets a real answer from a licensed pharmacist — free, and usually within a day.

Ask the pharmacist

Educational information only, not medical advice. Always confirm interactions with your pharmacist or prescriber before making any change to your medications.